CMS' Amyvid decision on the horizon

05/20/2013 | MolecularImaging.net

Eli Lilly & Co. and Avid Pharmaceuticals, the makers of the Alzheimer's imaging agent Amyvid, recently discussed the upcoming CMS draft decision on reimbursement for Amyvid and similar agents. Wei-Li Shao, senior director of Lilly's Alzheimer's business division, discussed three possible coverage decisions: continued non-coverage, coverage of amyloid PET imaging in full or coverage with evidence development. Shao said the decision could come between late June and the end of July. The companies said various groups including SNMMI have expressed support for CMS coverage.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA